Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer

Clinical trial NCT05656131 · SUSPENDED

Trial details

NCT number: NCT05656131
Sponsor: wang shusen
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

Start date: 2022-11-23
Primary completion: 2026-03-30
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.